Fibrinogen as a Binding Partner for Lecanemab Biosimilar IgG
Author Information
Author(s): J.‐P. Bellier, Román Viera Andrea M., Christiano Caitlyn, Anzai Juliana A. U., Moreno Stephanie, Campbell Emily C., Godwin Lucas, Li Amy, Chen Alan Y., Alam Sarah M., Saba Adriana, Yoo Han Bin, Yang Hyun‐Sik, Chhatwal Jasmeer P., Selkoe Dennis J., Liu Lei
Primary Institution: Department of Neurology, Brigham and Women's Hospital Harvard Medical School
Hypothesis
Does fibrinogen interact with lecanemab biosimilar IgG in human plasma?
Conclusion
Fibrinogen is identified as a significant plasma protein binding partner for lecanemab biosimilar IgG, which may affect its pharmacokinetics.
Supporting Evidence
- Fibrinogen was identified as a likely binding partner for lecanemab biosimilar IgG.
- Statistically significant disequilibrium ratios indicated binding of lecanemab to plasma components.
- Binding affinity of lecanemab to fibrinogen was estimated at 318 mM, significantly lower than its affinity for Aβ.
Takeaway
This study found that a protein called fibrinogen can stick to a medicine used for Alzheimer's, which might change how well the medicine works in the body.
Methodology
The study used equilibrium dialysis, ELISA, and western blotting to assess the binding of lecanemab biosimilar to plasma proteins.
Limitations
The study does not rule out the possibility of other plasma proteins binding to lecanemab.
Participant Demographics
15 participants aged 45 and older, including individuals with Alzheimer's and Parkinson's disease.
Statistical Information
P-Value
0.0312
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website